Viatris’ investigational blepharitis ointment failed to achieve the primary endpoint in its Phase III trial, prompting the company to reconsider the drug’s future.

Viatris said on Friday that its experimental eye ointment failed to clear buildup or debris in the eyes in a late-stage study in patients with an inflammatory eye condition.

By Katherine Hamilton Viatris's said on Friday that the trial of an ointment for people with blepharitis didn't meet its primary endpoint.

The Perfect Channel for Survival Game/Dinosaur Enthusiasts! This Channel is not "Family Friendly" and these videos are not intended for kids.

From TikTok virality to rhinestone-studded key chains, the humble healing ointment is having a high-gloss, Gen Z-fueled makeover.

115-years-old and thriving: Inside the wild revival of Aussie icon Lucas Papaw One of Australia’s oldest family businesses was on the brink of bust just five years ago. Now the 115-year-old ...

The British Museum (BM) is continuing to add notable names to its board of trustees with the appointment of the Apple trailblazer Jony Ive. As former chief design officer at the tech giant, the ...

In 2023, E45 committed to a new purpose: ‘to help everyone feel more comfortable in their skin.’ This commitment sparked a search for communities whose skin discomfort extended beyond the ...

Skincare brand E45 took home the Grand Prix at The Drum Awards for Marketing EMEA 2025 with a campaign that signaled deep insight, authentic representation and fearless allyship still matter. The ...

KKR & Co. agreed to acquire Swedish consumer-health company Karo Healthcare from EQT AB, defying the downbeat sentiment around dealmaking globally after US President Donald Trump unveiled his ...

--KKR is nearing a deal to buy E45 maker Karo Healthcare in a buyout that values the healthcare company at about 2.6 billion euros ($2.85 billion), Financial Times reports, citing unnamed sources.